The YouTuber suggests Pfizer is a buy due to its current low valuation (P/E of 12.99, P/B of 1.57) after a significant post-COVID decline, offering a high dividend yield of 7-7.5%. While acknowledging risks like high dividend payout ratio (89%) and declining cash flow, he believes the company's long history and potential for recovery make it an attractive long-term investment, especially given the margin of safety at current prices.
“Hoy vamos a hablar de Pfizer, una acción que para mi gusto está siendo muy castigada desde máximos que tuvo en COVID. Ha bajado en picado y creo que puede ser interesante.” — ▶ 00:00:07